The business model of AnaptysBio Inc is focused on discovering and developing novel antibody-based therapeutics for inflammation and immuno-oncology. With a strong emphasis on research and development, AnaptysBio utilizes its proprietary technology platform to generate highly specific therapeutic antibodies. These antibodies are aimed at targeting and modulating key immune system pathways to address various diseases, including inflammatory disorders, severe allergies, and certain types of cancers. By leveraging its expertise in antibody engineering and design, AnaptysBio aims to deliver innovative treatments that can improve patient outcomes and provide value to healthcare providers.

AnaptysBio Inc is primarily active in the biotechnology industry.

The main competitors of AnaptysBio Inc in the market are Regeneron Pharmaceuticals, Inc., Amgen Inc., and Novartis AG.

AnaptysBio Inc is a biotechnology company based in San Diego, California. Established in 2005, the company specializes in the discovery and development of therapeutic antibodies to address unmet medical needs. With a focus on inflammation, immuno-oncology, and rare diseases, AnaptysBio Inc utilizes its proprietary antibody discovery platform to identify and develop potential treatments. The company has forged collaborations with leading pharmaceutical companies and has a diverse pipeline of antibody candidates. AnaptysBio Inc's commitment to innovation and expertise in antibody-based therapies has positioned them as a prominent player in the biotech industry.

AnaptysBio Inc has achieved several significant milestones. The company has successfully developed novel antibody therapeutics for various severe diseases, including atopic dermatitis and peanut allergies. Additionally, AnaptysBio Inc has also entered into strategic collaborations with renowned pharmaceutical companies to further advance its drug pipeline. The company's dedication to research and development has led to the successful completion of multiple clinical trials, demonstrating their commitment to improving patient outcomes. With their innovative approach and strong partnerships, AnaptysBio Inc continues to pave the way in the field of biotechnology.

AnaptysBio Inc is primarily present in the United States.

AnaptysBio Inc represents a commitment to scientific innovation and excellence in the field of biotechnology. Its core values include a focus on discovering and developing novel antibody therapeutics to address unmet medical needs. The company strives to create value for patients, healthcare professionals, and shareholders through its cutting-edge research and development efforts. With a corporate philosophy centered around collaboration, AnaptysBio Inc aims to leverage its expertise and partnerships to drive forward breakthrough therapies that have the potential to improve patients' lives and revolutionize healthcare.

Analysts currently set an average price target of 65,87 USD for the AnaptysBio stock (median: 66,81 USD), implying +20,0 % versus the latest price. The consensus is based on 19 analyst ratings.

AnaptysBio Analyytikkojen kursstavoitteet 2026

19 analysts currently rate the AnaptysBio stock: 17 recommend buying, 2 holding and 0 selling. For 2026, analysts expect AnaptysBio to generate revenue of 94,28 M USD and earnings per share of −0,21 USD.

AnaptysBio Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the AnaptysBio share trades at 48,26 EUR (54,91 USD).

The AnaptysBio share (ANAB) is listed on 5 stock exchanges, including: NASDAQ (ANAB), Frankfurt (AN6.F), München (AN6.MU), Düsseldorf (AN6.DU), London (0HFQ.L).

AnaptysBio Inc is an innovative biotechnology company that focuses on the discovery and development of new biological therapeutics. The company was founded in 2005 in San Diego, California, and has since gained a leading position in the industry. The business model of AnaptysBio is based on the development of highly effective antibodies with a focus on inflammatory diseases and cancer. The scientists and developers at AnaptysBio use the latest technologies to identify and develop potential candidates in a rapid, precise, and cost-effective approach. AnaptysBio takes a differentiated approach to antibody identification and specializes in the development of biological therapeutics. AnaptysBio has a wide range of products, including Atrmab, ANB020, ANB019, and Etokimab. Atrmab is a nasal administration antibody product developed to treat allergic diseases such as hay fever. ANB020 is an antibody specifically targeting the treatment of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease. On the other hand, the antibody ANB019 is being developed as a therapy option for both Generalized Pustular Psoriasis (GPP) and Palmoplantar Pustular Psoriasis (PPP). Etokimab, on the other hand, aims to treat tessin and chronic pruritus. This is a non-specific skin disease characterized by constant itching and tingling. By developing innovative therapies, AnaptysBio is able to achieve significant advancements in the field of biological medicines. These therapeutics will help improve the lives of patients in various stages of the disease. AnaptysBio benefits from serving a small but rapidly growing niche in the industry. There is a high demand for specialized biological medicines, as these medicines are often more effective and better tolerated than traditional medicines and are therefore preferred by many doctors. AnaptysBio finances its business activities through investment capital and strategic partnerships with large pharmaceutical companies. In the early stages of biological therapeutic development, AnaptysBio plays an important role by conducting proof-of-concept studies and demonstrating the potential of new therapeutics. Once the therapeutics move into clinical phases, pharmaceutical companies seek collaborations to conduct joint clinical trials and enter the market. Overall, AnaptysBio is a successful biotech company that is capable of revolutionizing therapy approaches for inflammatory and cancerous diseases. Through collaboration with large pharmaceutical companies and the development of innovative products, AnaptysBio is in a strong position to achieve further growth and success.

odotettu liikevaihto AnaptysBio on 94,28 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto AnaptysBio on −6,63 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

AnaptysBio:n hinta-voitto-suhde (P/E) on tällä hetkellä −259,41. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan AnaptysBio-osakkeen arvostusta.

AnaptysBio:n hinta-myynti-suhde (P/S) on tällä hetkellä 18,26. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii AnaptysBio-osakkeen arvostuskennuslukuna.

AnaptysBio:n Eulpool-laatuscore on 6/10.

AnaptysBio:n ISIN on US0327241065. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

AnaptysBio:n WKN on A2AJ8C. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

AnaptysBio:n ticker on ANAB. Tämä pörssinoteeraus käytetään AnaptysBio-osakkeiden kauppaan pörssissä.

AnaptysBio maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

AnaptysBio kuuluu sektoriin 'Terveydenhuolto'.

AnaptysBio:n osingot jaetaan valuutassa USD.